Cargando…

Mineral and bone metabolism markers and mortality in diabetic patients on haemodialysis

BACKGROUND: Diabetic patients on haemodialysis have a higher risk of mortality than non-diabetic patients. The aim of this COSMOS (Current management of secondary hyperparathyroidism: a multicentre observational study) analysis was to assess whether bone and mineral laboratory values [calcium, phosp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martín-Carro, Beatriz, Navarro-González, Juan F, Ortiz, Alberto, Zoccali, Carmine, Floege, Jürgen, Ferreira, Manuel A, Gorriz-Teruel, José L, Carrillo-López, Natalia, Panizo, Sara, Locatelli, Francesco, Ketteler, Markus, London, Gerard M, Naves-Díaz, Manuel, Alonso-Montes, Cristina, Cannata-Andía, Jorge B, Fernández-Martín, José L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615625/ https://www.ncbi.nlm.nih.gov/pubmed/37349949 http://dx.doi.org/10.1093/ndt/gfad122

Ejemplares similares

Survival with low- and high-flux dialysis
por: Sánchez-Álvarez, Emilio, et al.
Publicado: (2020)

Fibrosis in Chronic Kidney Disease: Pathogenesis and Consequences
por: Panizo, Sara, et al.
Publicado: (2021)

Vascular calcifications, vertebral fractures and mortality in haemodialysis patients
por: Rodríguez-García, Minerva, et al.
Publicado: (2009)

Phosphorus May Induce Phenotypic Transdifferentiation of Vascular Smooth Muscle Cells through the Reduction of microRNA-145
por: Fernández-Villabrille, Sara, et al.
Publicado: (2023)

Experimental Models to Study Diabetes Mellitus and Its Complications: Limitations and New Opportunities
por: Martín-Carro, Beatriz, et al.
Publicado: (2023)

MicroRNA-145 and microRNA-486 are potential serum biomarkers for vascular calcification
por: Fernández-Villabrille, Sara, et al.
Publicado: (2023)

Role of Klotho and AGE/RAGE-Wnt/β-Catenin Signalling Pathway on the Development of Cardiac and Renal Fibrosis in Diabetes
por: Martín-Carro, Beatriz, et al.
Publicado: (2023)

Serum and Urinary Soluble α-Klotho as Markers of Kidney and Vascular Impairment
por: Martín-Vírgala, Julia, et al.
Publicado: (2023)

Simplifying volume assessment with lung ultrasound in paediatric haemodialysis patients
por: Loutradis, Charalampos, et al.
Publicado: (2020)

Cardiovascular and renal medicine, an expanding territory
por: Zoccali, Carmine, et al.
Publicado: (2011)

Redox Metabolism and Vascular Calcification in Chronic Kidney Disease
por: Carrillo-López, Natalia, et al.
Publicado: (2023)

The European Certificate in Nephrology: towards harmonization and excellence in training
por: Cannata-Andía, Jorge B, et al.
Publicado: (2018)

Effects of a Losartan-Antioxidant Hybrid (GGN1231) on Vascular and Cardiac Health in an Experimental Model of Chronic Renal Failure
por: Martínez-Arias, Laura, et al.
Publicado: (2023)

Pathophysiology of Vascular Calcification and Bone Loss: Linked Disorders of Ageing?
por: Cannata-Andía, Jorge B., et al.
Publicado: (2021)

The Pathophysiology of Secondary Hyperparathyroidism and the Consequences of Uncontrolled Mineral Metabolism in Chronic Kidney Disease: The Role of COSMOS
por: Cannata-Andía, Jorge B., et al.
Publicado: (2008)

Vitamin D Treatment Prevents Uremia-Induced Reductions in Aortic microRNA-145 Attenuating Osteogenic Differentiation despite Hyperphosphatemia
por: Carrillo-López, Natalia, et al.
Publicado: (2022)

Novel Immune Cell Subsets Exhibit Different Associations With Vascular Outcomes in Chronic Kidney Disease Patients—Identifying Potential Biomarkers
por: Rodríguez-Carrio, Javier, et al.
Publicado: (2021)

Klotho, Oxidative Stress, and Mitochondrial Damage in Kidney Disease
por: Donate-Correa, Javier, et al.
Publicado: (2023)

The future of European Nephrology ‘Guidelines’—a declaration of intent by European Renal Best Practice (ERBP)
por: Vanholder, Raymond, et al.
Publicado: (2009)

Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease–mineral bone disorder parameters in dialysis patients
por: Ketteler, Markus, et al.
Publicado: (2019)

A single-oral bolus of 100,000 IU of cholecalciferol at hospital admission did not improve outcomes in the COVID-19 disease: the COVID-VIT-D—a randomised multicentre international clinical trial
por: Cannata-Andía, Jorge B., et al.
Publicado: (2022)

Vitamin D Receptor Polymorphism and DHCR7 Contribute to the Abnormal Interplay Between Vitamin D and Lipid Profile in Rheumatoid Arthritis
por: Rodríguez-Carrio, Javier, et al.
Publicado: (2019)

Management of hyperphosphataemia in chronic kidney disease—challenges and solutions
por: Ketteler, Markus, et al.
Publicado: (2013)

Cinacalcet-induced hypocalcemia in a cohort of European haemodialysis patients: predictors, therapeutic approaches and outcomes
por: Louie, Karly S., et al.
Publicado: (2019)

Plasma Cardiotrophin-1 as a Marker of Hypertension and Diabetes-Induced Target Organ Damage and Cardiovascular Risk
por: Gamella-Pozuelo, Luis, et al.
Publicado: (2015)

Consideraciones respecto a ezetimiba y deterioro renal
por: Pallarés-Carratalá, Vicente, et al.
Publicado: (2015)

Efficacy of enoxaparin in preventing coagulation during high-flux haemodialysis, expanded haemodialysis and haemodiafiltration
por: Santos, Alba, et al.
Publicado: (2020)

Survival of patients treated with extended-hours haemodialysis in Europe: an analysis of the ERA-EDTA Registry
por: Jansz, Thijs T, et al.
Publicado: (2019)

Assessing value‐based health care delivery for haemodialysis
por: Parra, Eduardo, et al.
Publicado: (2015)

Predictors of haemoglobin levels and resistance to erythropoiesis-stimulating agents in patients treated with low-flux haemodialysis, haemofiltration and haemodiafiltration: results of a multicentre randomized and controlled trial
por: Locatelli, Francesco, et al.
Publicado: (2012)

Survival on four compared with three times per week haemodialysis in high ultrafiltration patients: an observational study
por: Fotheringham, James, et al.
Publicado: (2020)

Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study
por: Ketteler, Markus, et al.
Publicado: (2012)

Promoting scientific collaboration and education in cardiovascular–renal medicine: EURECAM: An ERA-EDTA-based working group
por: Covic, Adrian, et al.
Publicado: (2009)

SARS-CoV-2 infection in patients with chronic kidney disease on haemodialysis. Evolution of SARS-CoV-2 CRP()
por: Zúñiga, José, et al.
Publicado: (2021)

Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population
por: Floege, Jürgen, et al.
Publicado: (2011)

Clinical Outcomes in Secondary Hyperparathyroidism and the Potential Role of Calcimimetics
por: Cunningham, John, et al.
Publicado: (2008)

Barley-ß-glucans reduce systemic inflammation, renal injury and aortic calcification through ADAM17 and neutral-sphingomyelinase2 inhibition
por: Arcidiacono, Maria Vittoria, et al.
Publicado: (2019)

Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant polycystic kidney disease
por: Gorriz, José Luis, et al.
Publicado: (2021)

Deciphering the core elements around haemodialysis therapy
por: Bowry, Sudhir K, et al.
Publicado: (2021)

Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study
por: Ketteler, Markus, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_fd4g19s6s9jq0cu8eb1fmrmg43